Figure 4.

Immmunotherapy of surgical minimal residual tumor disease of TC-1 and TRAMP-C2 tumors with DC-based vaccine. (A) Mice were inoculated s.c. with TC-1 (5 × 10⁴ cells) or TRAMP-C2 (10⁶ cells). When the transplanted tumors reached ∼5–10 mm in diameter, the tumors were excised. DC-based vaccines (2 × 10⁶ cells/mouse) were administered on days 7 and 21 after surgery (left panel). In the case of pretreatment, DC-based vaccines (2 × 10⁶ cells/mouse) were additionally administered on days -7 (TC-1, TRAMP-C2) and -21 (TRAMP-C2) before surgery (right panel) (B) Growth of TRAMP-C2 tumor recurrences after treatment with unpulsed and pulsed DC-based vaccine (left panel) and the growth of TRAMP-C2 tumor recurrences after pre-treatment or treatment with pulsed DC-based vaccine (right panel). (C) Growth of TC-1 tumor recurrences after treatment with unpulsed and pulsed DC-based vaccine (left panel) and the growth of TC-1 tumor recurrences after pre-treatment or treatment with pulsed DC-based vaccine (right panel). *P<0.05 vs. control (Analysis of Variance).